165 related articles for article (PubMed ID: 33659716)
1. Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy.
Stick LB; Lorenzen EL; Yates ES; Anandadas C; Andersen K; Aristei C; Byrne O; Hol S; Jensen I; Kirby AM; Kirova YM; Marrazzo L; Matías-Pérez A; Nielsen MMB; Nissen HD; Oliveros S; Verhoeven K; Vikström J; Offersen BV
Clin Transl Radiat Oncol; 2021 Mar; 27():126-131. PubMed ID: 33659716
[TBL] [Abstract][Full Text] [Related]
2. Proton therapy for early breast cancer patients in the DBCG proton trial: planning, adaptation, and clinical experience from the first 43 patients.
Fuglsang Jensen M; Stick LB; Høyer M; Kronborg CJS; Lorenzen EL; Mortensen HR; Nyström PW; Petersen SE; Randers P; Thai LMH; Yates ES; Offersen BV
Acta Oncol; 2022 Feb; 61(2):223-230. PubMed ID: 34632922
[TBL] [Abstract][Full Text] [Related]
3. Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial.
Thomsen MS; Berg M; Zimmermann S; Lutz CM; Makocki S; Jensen I; Hjelstuen MHB; Pensold S; Hasler MP; Jensen MB; Offersen BV
Clin Transl Radiat Oncol; 2021 May; 28():118-123. PubMed ID: 33937532
[TBL] [Abstract][Full Text] [Related]
4. Volumetric arc therapy: A viable option for right-sided breast with comprehensive regional nodal irradiation in conjunction with deep inspiration breath hold.
Holt E; Mantel A; Cokelek M; Tacey M; Jassal S; Law M; Zantuck N; Yong C; Cheng M; Viotto A; Foroudi F; Chao M
J Med Imaging Radiat Sci; 2021 Jun; 52(2):223-237. PubMed ID: 33771509
[TBL] [Abstract][Full Text] [Related]
5. The potential benefits from respiratory gating for breast cancer patients regarding target coverage and dose to organs at risk when applying strict dose limits to the heart: results from the DBCG HYPO trial.
Berg M; Lorenzen EL; Jensen I; Thomsen MS; Lutz CM; Refsgaard L; Nissen HD; Offersen BV
Acta Oncol; 2018 Jan; 57(1):113-119. PubMed ID: 29205080
[TBL] [Abstract][Full Text] [Related]
6. CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects.
Thorsen LB; Thomsen MS; Berg M; Jensen I; Josipovic M; Overgaard M; Overgaard J; Skogholt P; Offersen BV;
Acta Oncol; 2014 Aug; 53(8):1027-34. PubMed ID: 24957557
[TBL] [Abstract][Full Text] [Related]
7. Quality assurance of conventional non-CT-based internal mammary lymph node irradiation in a prospective Danish Breast Cancer Cooperative Group trial: the DBCG-IMN study.
Thorsen LB; Thomsen MS; Overgaard M; Overgaard J; Offersen BV;
Acta Oncol; 2013 Oct; 52(7):1526-34. PubMed ID: 23957621
[TBL] [Abstract][Full Text] [Related]
8. Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular- and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk.
Hjelstuen MH; Mjaaland I; Vikström J; Dybvik KI
Acta Oncol; 2012 Mar; 51(3):333-44. PubMed ID: 22171587
[TBL] [Abstract][Full Text] [Related]
9. A Randomised Phase II Clinical Trial Comparing the Deliverability and Acute Toxicity of Wide Tangent versus Volumetric Modulated Arc Therapy to the Breast and Internal Mammary Chain.
Ranger A; Dunlop A; Hansen VN; Princewill G; Landeg S; Donovan EM; Harris EJ; McNair HA; Haviland J; Kirby AM
Clin Oncol (R Coll Radiol); 2022 Aug; 34(8):526-533. PubMed ID: 35597698
[TBL] [Abstract][Full Text] [Related]
10. What Can Proton Beam Therapy Achieve for Patients with Pectus Excavatum Requiring Left Breast, Axilla and Internal Mammary Nodal Radiotherapy?
Settatree S; Dunlop A; Mohajer J; Brand D; Mooney L; Ross G; Gulliford S; Harris E; Kirby A
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e570-e577. PubMed ID: 34226114
[TBL] [Abstract][Full Text] [Related]
11. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes.
Lomax AJ; Cella L; Weber D; Kurtz JM; Miralbell R
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):785-92. PubMed ID: 12573766
[TBL] [Abstract][Full Text] [Related]
12. Internal mammary node coverage: an investigation of presently accepted techniques.
Arthur DW; Arnfield MR; Warwicke LA; Morris MM; Zwicker RD
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):139-46. PubMed ID: 10924983
[TBL] [Abstract][Full Text] [Related]
13. Impact of patient and treatment characteristics on heart and lung dose in adjuvant radiotherapy for left-sided breast cancer.
Finazzi T; Nguyen VT; Zimmermann F; Papachristofilou A
Radiat Oncol; 2019 Aug; 14(1):153. PubMed ID: 31462267
[TBL] [Abstract][Full Text] [Related]
14. Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study.
Pandeli C; Smyth LML; David S; See AW
Radiat Oncol; 2019 Dec; 14(1):223. PubMed ID: 31822293
[TBL] [Abstract][Full Text] [Related]
15. Initial Report of a Prospective Dosimetric and Clinical Feasibility Trial Demonstrates the Potential of Protons to Increase the Therapeutic Ratio in Breast Cancer Compared With Photons.
Bradley JA; Dagan R; Ho MW; Rutenberg M; Morris CG; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):411-421. PubMed ID: 26611875
[TBL] [Abstract][Full Text] [Related]
16. The role of breath hold intensity modulated proton therapy for a case of left-sided breast cancer with IMN involvement. How protons compare with other conformal techniques?
Lee HL; Lim LH; Master Z; Wong SMM
Tech Innov Patient Support Radiat Oncol; 2020 Sep; 15():1-5. PubMed ID: 32490219
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.
Offersen BV; Alsner J; Nielsen HM; Jakobsen EH; Nielsen MH; Krause M; Stenbygaard L; Mjaaland I; Schreiber A; Kasti UM; Overgaard J;
J Clin Oncol; 2020 Nov; 38(31):3615-3625. PubMed ID: 32910709
[TBL] [Abstract][Full Text] [Related]
18. Deep inspiration breath-hold produces a clinically meaningful reduction in ipsilateral lung dose during locoregional radiation therapy for some women with right-sided breast cancer.
Conway JL; Conroy L; Harper L; Scheifele M; Li H; Smith WL; Graham T; Phan T; Olivotto IA
Pract Radiat Oncol; 2017; 7(3):147-153. PubMed ID: 28089480
[TBL] [Abstract][Full Text] [Related]
19. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
[TBL] [Abstract][Full Text] [Related]
20. Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer.
Cuaron JJ; Chon B; Tsai H; Goenka A; DeBlois D; Ho A; Powell S; Hug E; Cahlon O
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):284-91. PubMed ID: 25754632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
